Head, Market Access
Orca BioFull Time
Expert & Leadership (9+ years)
Candidates must possess a Bachelor's degree and have deep expertise in oncology diagnostics, payer engagement, and global reimbursement landscapes. Experience in developing global market access strategies for oncology diagnostic solutions, including comprehensive genomic profiling, liquid biopsy, and companion diagnostics, is essential. Familiarity with emerging oncology testing applications and indications like WGS, MRD, and early detection is required. Proven ability to collaborate across regions and functions to shape value narratives, secure reimbursement, and drive adoption in diverse healthcare systems is necessary.
The Director, Global Market Access Strategy – Oncology will lead the development of global market access strategies for Illumina's oncology diagnostic solutions, covering hereditary risk testing, solid and liquid tumor profiling, and monitoring. Responsibilities include partnering with regional teams to secure reimbursement and access in key markets, collaborating with internal teams to align and execute strategies for gaining and expanding access, and defining and communicating the clinical and economic value of diagnostics. The role also involves supporting evidence generation strategies, monitoring global policy trends and HTA requirements, developing value dossiers and payer engagement materials, building relationships with external stakeholders, and providing strategic input into product development and lifecycle management. Additionally, the Director will lead product coding and pricing efforts and ensure compliance with relevant standards.
Supports genomics startups through funding and resources
Illumina focuses on fostering innovation in the genomics industry by supporting startups through its Illumina Accelerator program. This program helps entrepreneurs create, launch, and grow genomics-focused companies by providing funding and resources. The accelerator operates in two main locations: the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator has successfully invested in 68 genomics startups, which have collectively raised over $1 billion in venture capital. What sets Illumina apart from its competitors is its strong partnership with leading venture capital investors and its dedicated focus on the genomics sector. The goal of Illumina is to build a thriving ecosystem for genomics innovation, enabling new companies to emerge and advance the field.